TipRanks
Advertisement
Advertisement

VYGR Stock Latest News

Voyager Therapeutics: Buy Rating Reiterated as Alzheimer’s Pipeline Advances; $25 Price Target Maintained
RatingsVoyager Therapeutics: Buy Rating Reiterated as Alzheimer’s Pipeline Advances; $25 Price Target Maintained
24d ago
VYGR
Voyager’s New Alzheimer’s Trial Puts VYGR on Investors’ Early Watchlist
PremiumCompany Announcements
Voyager’s New Alzheimer’s Trial Puts VYGR on Investors’ Early Watchlist
1M ago
VYGR
Voyager Therapeutics Reaffirmed Buy on Advancing Alzheimer’s Pipeline and 4Q26 Tau Program Catalysts; $8 Price Target Maintained
PremiumRatings
Voyager Therapeutics Reaffirmed Buy on Advancing Alzheimer’s Pipeline and 4Q26 Tau Program Catalysts; $8 Price Target Maintained
1M ago
VYGR
Voyager Therapeutics reports Q2 EPS (40c), consensus (51c)
PremiumThe Fly
Voyager Therapeutics reports Q2 EPS (40c), consensus (51c)
1M ago
VYGR
Voyager Therapeutics: Buy Rating Reaffirmed and $25 Price Target Maintained on Tau Therapy Leadership and Upcoming Clinical Milestones
PremiumRatings
Voyager Therapeutics: Buy Rating Reaffirmed and $25 Price Target Maintained on Tau Therapy Leadership and Upcoming Clinical Milestones
2M ago
VYGR
Voyager Therapeutics advances tau-silencing gene therapy program
PremiumCompany AnnouncementsVoyager Therapeutics advances tau-silencing gene therapy program
2M ago
8K
VYGR
Voyager Therapeutics presents six-month toxicology data for VY1706
Premium
The Fly
Voyager Therapeutics presents six-month toxicology data for VY1706
2M ago
VYGR
Voyager Therapeutics Expands Authorized Shares After Stockholder Vote
Premium
Company Announcements
Voyager Therapeutics Expands Authorized Shares After Stockholder Vote
3M ago
8K
VYGR
Voyager Therapeutics announces FDA clearance for VY1706 IND application
PremiumThe Fly
Voyager Therapeutics announces FDA clearance for VY1706 IND application
4M ago
VYGR
Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy
PremiumCompany Announcements
Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy
4M ago
8K
VYGR
Voyager Therapeutics: Advancing CNS Gene Therapy Pipeline and TRACER Platform Underpin Buy Rating and Unchanged $25 Price Target
PremiumRatings
Voyager Therapeutics: Advancing CNS Gene Therapy Pipeline and TRACER Platform Underpin Buy Rating and Unchanged $25 Price Target
4M ago
VYGR
Voyager awarded new mission management contract with Exobiosphere
PremiumThe Fly
Voyager awarded new mission management contract with Exobiosphere
4M ago
VYGR
Voyager Therapeutics presents GLP for toxicology data for VY1706
PremiumThe FlyVoyager Therapeutics presents GLP for toxicology data for VY1706
4M ago
VYGR
Voyager Therapeutics Warns of Broad Risk Exposure and Uncertain Outlook in Latest SEC Filings
Premium
Company Announcements
Voyager Therapeutics Warns of Broad Risk Exposure and Uncertain Outlook in Latest SEC Filings
4M ago
VYGR
Analyst Reaffirms Buy on Voyager Therapeutics as Strong Cash Runway and Advancing Neurology Pipeline Set Up Multiple 2026 Catalysts
Premium
Ratings
Analyst Reaffirms Buy on Voyager Therapeutics as Strong Cash Runway and Advancing Neurology Pipeline Set Up Multiple 2026 Catalysts
5M ago
VYGR
Voyager Therapeutics reports Q1 EPS (47c), consensus (53c)
PremiumThe Fly
Voyager Therapeutics reports Q1 EPS (47c), consensus (53c)
5M ago
VYGR
Voyager Therapeutics management to meet with Oppenheimer
PremiumThe Fly
Voyager Therapeutics management to meet with Oppenheimer
5M ago
VYGR
Voyager Therapeutics Announces CFO Resignation and Finance Leadership Changes
PremiumCompany Announcements
Voyager Therapeutics Announces CFO Resignation and Finance Leadership Changes
5M ago
8K
VYGR
Amazon (AMZN) Launches AI Tools to Help Accelerate Drug Discoveries
PremiumMarket News
Amazon (AMZN) Launches AI Tools to Help Accelerate Drug Discoveries
5M ago
NVO
AMZN
Voyager Therapeutics management to meet with Oppenheimer
PremiumThe FlyVoyager Therapeutics management to meet with Oppenheimer
5M ago
VYGR
Voyager Therapeutics: Early-Stage Tau Program Optionality Drives High-Risk, High-Upside Buy Rating
Premium
Ratings
Voyager Therapeutics: Early-Stage Tau Program Optionality Drives High-Risk, High-Upside Buy Rating
6M ago
VYGR
Voyager Therapeutics: Differentiated CNS Platform, Strategic Partnerships, and 2026 Data Catalysts Underpin Buy Rating
Premium
Ratings
Voyager Therapeutics: Differentiated CNS Platform, Strategic Partnerships, and 2026 Data Catalysts Underpin Buy Rating
6M ago
VYGR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >